Yang Zhou

Yang Zhou

Auto-generated profile, based on publicly available information

Yang Zhou

Department of Pathology, The Second People’s Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, Changzhou, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LZLufeng Zheng
Lufeng Zheng
YZYuxin Zhang
Yuxin Zhang
SMShuang Mei
Shuang Mei
TXTianyuan Xie
Tianyuan Xie
YZYunting Zou
Yunting Zou
MNMiao-Miao Niu
Miao-Miao Niu

22 December 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YWYuting Wang
Yuting Wang
HZHai Zhang
Hai Zhang
JLJindong Li
Jindong Li
MNMiao-Miao Niu
Miao-Miao Niu
YZYang Zhou
Yang Zhou
YQYuanqian Qu
Yuanqian Qu
KRASG12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of pancreatic cancer. Herein, we identified four potent and noncovalent KRASG12D inhibitors (hits 1–4) by using structure-based virtual screening and biological evaluation. The in vitro assays indicated that the four compounds had sub-nanomolar affinities for KRASG12D and showed a dose-dependent inhibitory effect on human pancreatic cancer cells. In particular, the hit compound 3 was the most promising candidate and significantly inhibited the tumor growth of pancreatic cancer in tumor-bearing mice. The hit compound 3 represented a promising starting point for structural optimization in hit-to-lead development. This study shows that hit compound 3 provides a basis for the development of the treatment of cancer driven by KRASG12D.

15 May 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NJNan Jiang
Nan Jiang
MLMengting Lou
Mengting Lou
NWNan Wu
Nan Wu
YGYifei Geng
Yifei Geng
MNMiao-Miao Niu
Miao-Miao Niu
SZShizhu Zhang
Shizhu Zhang

10 July 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
YYYingxue Yang
Yingxue Yang
SCShutong Chen
Shutong Chen
QWQinghua Wang
Qinghua Wang
MNMiao-Miao Niu
Miao-Miao Niu
YQYuanqian Qu
Yuanqian Qu
YZYang Zhou
Yang Zhou
Cancer is one of the important factors threatening human health. Hence, it is essential to create novel potent drugs to treat it. Due to the strong correlation among histone deacetylase1 (HDAC1), speckle-type POZ protein (SPOP) and cancers, dual inhibition of HDAC1 and SPOP may be a promising strategy for cancer treatment. In this study, we successfully identified four potential dual-targeting HDAC1/SPOP candidate compounds with structure-based virtual screening. In vitro inhibition experiments confirmed that the four compounds had dual inhibitory effects on HDAC1 and SPOP. Among them, compound HS-2 had a stronger inhibitory effect on HDAC1 and SPOP than the positive controls. Further molecular dynamics simulations indicated that HS-2 could stably bind to HDAC1 and SPOP. In addition, MTT assay indicated that HS-2 inhibited the growth of tumor cells in the micromolar range. In vivo evaluation showed that HS-2 could obviously inhibit the growth of tumor in nude mice without obvious toxicity. These findings suggest that HS-2 is a novel and potent dual-targeting HDAC1/SPOP inhibitor for cancer treatment.

25 February 2025 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
YZYang Zhou
Yang Zhou
YWYuting Wang
Yuting Wang
JLJuanjuan Liu
Juanjuan Liu
YBYu Bai
Yu Bai
JMJinliang Ma
Jinliang Ma
HJHaijing Jiang
Haijing Jiang

12 September 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
TZTianhan Zhou
Tianhan Zhou
YZYang Zhou
Yang Zhou
ZNZhongkai Ni
Zhongkai Ni
HFHao Fang
Hao Fang
FWFan Wu
Fan Wu
HHHai Huang
Hai Huang
Accurate preoperative assessment of central lymph node metastasis (CLNM) in papillary thyroid carcinoma (PTC) remains challenging. This retrospective study was registered at ClinicalTrials.gov (NCT06725628) on December 9, 2024. A total of 934 patients with confirmed PTC who underwent cervical central lymph node dissection between January 2023 and December 2024 were included. Radiomics features were extracted and selected. Deep learning models were trained and used for automatic segmentation and classification. We developed and validated a Thy-CLNM Fusion model, which achieved an AUC of 0.862, with a sensitivity of 78.9% and a specificity of 79.3% in the validation cohort. We compared the proposed model with other models that also predict CLNM, and the results demonstrated competitive performance compared with previously reported models. Histopathological slides from 231 patients were retrospectively reviewed to provide pathological interpretability. In the CLNM low-risk group, model activation predominantly localized to hyperechoic Habitat I regions, corresponding pathologically to fibrous hyperplasia and active lymphocyte–tumor cell interactions. In the CLNM high-risk group, model attention showed dominant localization in hypoechoic Habitat II regions, which were associated with nuclear atypia, poor differentiation, reduced intercellular adhesion, and vascular invasion. The proposed model offers an additional preoperative decision-support option for CLNM risk assessment in PTC patients who are planning to undergo surgery and are being considered for central lymph node dissection.